Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 5:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 1,549 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ulcers Clear all
Completed No phase listed Observational

A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk

NCT00013286
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Prevention Diabetic Foot Ulcer
Device
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 29, 2026, 5:29 AM EDT
Terminated Phase 1 Interventional

Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

NCT03656627
View directory record Official record
Conditions
Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis
Interventions
Nivolumab
Drug
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Chicago, Illinois • Boston, Massachusetts • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 29, 2026, 5:29 AM EDT
Completed Not applicable Interventional Results available

Wheeled Mobility for Preventing Pressure Ulcers

NCT01275313
View directory record Official record
Conditions
Mobility Limitation
Interventions
Lightweight wheelchair, Skin Protection Cushion
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 29, 2026, 5:29 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

NCT03006068
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Upadacitinib (ABT-494), Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 75 Years
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
147
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 29, 2026, 5:29 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers

NCT00651586
View directory record Official record
Conditions
Acute Bacterial Corneal Ulcers, Bacterial Keratitis
Interventions
Gatifloxacin 0.3% ophthalmic solution, Ciprofloxacin 0.3% ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
8 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Oct 29, 2026, 5:29 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Studying the Relationship Between Contact Lens Packaging Solutions and Bacterial Binding to Surface Eye Cells

NCT01104961
View directory record Official record
Conditions
Corneal Ulcer
Interventions
Contact lens packaging solution, Balanced salt solution (BSS)
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 38 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 29, 2026, 5:29 AM EDT
Terminated Not applicable Interventional

An Open, Non-comparative, Multicenter Investigation to Evaluate the Safety and Performance of Exufiber Ag+, a Gelling Fiber Silver Dressing, When Used in Medium to High Exuding Chronic Wounds

NCT05494450
View directory record Official record
Conditions
Pressure Ulcer, Diabetic Foot Ulcer, Venous Leg Ulcer
Interventions
ExufiberAG+
Device
Lead sponsor
Molnlycke Health Care AB
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
2
States / cities
San Francisco, California • Miamisburg, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 29, 2026, 5:29 AM EDT
Recruiting Phase 1Phase 2 Interventional

Treatment of Moderate to Severe Refractory Crohn's Disease

NCT06721962
View directory record Official record
Conditions
Crohns Disease
Interventions
TRX103, Cyclophosphamide
Biological · Drug
Lead sponsor
Tr1X, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
13
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 29, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Thalidomide to Treat Oral Lesions in HIV-Infected Patients

NCT00001524
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Burning Mouth Syndrome, HIV Infection
Interventions
Thalidomide
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 5:29 AM EDT
Not listed Phase 2 Interventional

Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers

NCT04186559
View directory record Official record
Conditions
Behcet Syndrome, Behcet Disease
Interventions
Topical Pentoxifylline Gel (Vehicle +PTX), Topical Placebo Gel (Vehicle)
Drug
Lead sponsor
Silk Road Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 29, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors

NCT02100696
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Etrozulimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
38
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 29, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)

NCT03558152
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
UTTR1147A, UTTR1147A Placebo, Vedolizumab, Vedolizumab Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Greenville, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 29, 2026, 5:29 AM EDT
Recruiting Phase 2 Interventional

A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

NCT07470879
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Etrasimod
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
10
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 5:29 AM EDT
Completed Not applicable Interventional Results available

Alternating Pressure Overlay on Weight Bearing Tissue Tolerance in People With Spinal Cord Injury

NCT03317288
View directory record Official record
Conditions
Spinal Cord Injuries, Pressure Ulcer
Interventions
Dabir Air overlay
Device
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 29, 2026, 5:29 AM EDT
Terminated Phase 1 Interventional

A Study of Asacol Absorption, Metabolism and Excretion in Children and Adolescents With Ulcerative Colitis.

NCT00254618
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
5 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Costa Mesa, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 29, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

NCT04505410
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention
Other · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 29, 2026, 5:29 AM EDT
Withdrawn Phase 2 Interventional

Hydroxocobalamin Approach for Reducing of Calprotectin With Butyrate for Ulcerative Colitis Remission

NCT04259060
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Hydroxocobalamin with Butyrate, Placebo with Butyrate
Drug
Lead sponsor
Joshua Korzenik
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 29, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

NCT02163759
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adalimumab, Adalimumab Placebo, Etrolizumab, Etrolizumab Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
Lakewood, Colorado • Maitland, Florida • Naples, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 29, 2026, 5:29 AM EDT
Completed Phase 2 Interventional Results available

Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis

NCT01393405
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Methotrexate
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
31
States / cities
Los Angeles, California • Denver, Colorado • Winter Park, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 29, 2026, 5:29 AM EDT
Terminated Not applicable Interventional Results available

A Prospective, Open Label, Multicenter Trial for Evaluating the Efficacy of Treating and Managing Wounds in Elderly Population in Specialized Nursing Facilities Using RD1

NCT04577183
View directory record Official record
Conditions
Diabetic Foot Ulcer, Pressure Ulcer, Venous Leg Ulcer, Trauma Injury, Skin Tear, Chronic Ulcer
Interventions
RD1 System
Device
Lead sponsor
RedDress Ltd.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Butler, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 29, 2026, 5:29 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

NCT02065557
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Adalimumab, Placebo
Biological
Lead sponsor
AbbVie
Industry
Eligibility
4 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 29, 2026, 5:29 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Non-Invasive Testing to Evaluate Wound Healing in Diabetes

NCT04232631
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
SnapshotNIR, Kent Imaging
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 29, 2026, 5:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing Pressure Ulcers With Repositioning Frequency and Precipitating Factors

NCT02996331
View directory record Official record
Conditions
Pressure Ulcer
Interventions
2 hour repositioning, 3 hour repositioning, 4 hour repositioning
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
2,113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Wallingford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Oct 29, 2026, 5:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers

NCT00392080
View directory record Official record
Conditions
Osteoarthritis
Interventions
CJ-023,423, placebo, naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
11
States / cities
Anaheim, California • San Diego, California • Jupiter, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2008 · Synced Oct 29, 2026, 5:29 AM EDT